Long Position on TBIO @ $28.00 on 7/2/2021 (Momentum)

Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. 

The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2.

The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017.

Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.

Translate Bio reported a 1st Quarter March 2021 loss of $0.10 per share on revenue of $34.6 million. The consensus estimate was a loss of $0.09 per share on revenue of $36.3 million. Revenue grew 643.4% on a year-over-year basis.

Transgenomic Inc is a biotechnology company. It provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services.

This stock should see an increase in share prices as it is signals high price strength.

Entry Point: $27.75

Stop Loss: $26.40

Trading Range: $11.91 - $34.64

Target Price: $30.50

Updates

7/23/2021 9:36:59 AM

TBIO closed at $30.70

Position closed on 7/23/2021 at price of $30.70 with a 9.64% gain in 21 days.

Back to Portfolio